Ferric oxide

Ferric Oxide (Iron(III) Oxide, Fe₂O₃): A Comprehensive Reference

1. Identity, Chemistry, and Natural Sources

1.1 Chemical Identity and Nomenclature

Ferric oxide, also known by the IUPAC name iron(III) oxide, is an inorganic compound represented by the chemical formula Fe₂O₃. It is one of the most important oxides of iron, the other two being ferrosoferric oxide (Fe₃O₄) and ferrous oxide (FeO).

The term ferric indicates that iron is in the +3 oxidation state. It is also sometimes called iron(III) oxide, since the Roman numeral indicates that iron is in the +3 oxidation state. A molecule of ferric oxide (Fe₂O₃) contains two ferric ions (Fe³⁺) and three oxygen ions (O^2–).

The compound is known by a wide array of synonyms in different contexts. Other names include: hematite, ferric iron, red iron oxide, rouge, maghemite, colcothar, rust, and ochre. As a colorant, it carries designations including CI Pigment Red 101; CI (1975) No 77491; and INS No 172(ii).

Physically, ferric oxide is a reddish-brown hexagonal crystal with a refractive index of 2.91, a density of 5.25 g/cm³, Mohs hardness of 6.0, and a melting point of 1,565°C. Color is one key difference between ferrous oxide, which is black, and ferric oxide, which is red.

1.2 Natural Occurrence and Mineral Sources

Iron(III) oxide occurs in nature as the mineral hematite. It is the principal ore of iron from which the metal and its alloys are produced. It is the most abundant iron oxide mineral on Earth's surface and in the shallow crust, found in sedimentary, metamorphic, and igneous rocks worldwide.

The oxide also occurs in the mineral limonite (2Fe₂O₃·3H₂O). It is also known as hydrous ferric oxide and can be chemically represented as Fe₂O₃·H₂O or Fe(O)OH. Some common forms of the hydrated ferric oxide include red lepidocrocite (occurring externally in rusticles) and orange goethite (occurring on the inside of rusticles).

Its iron content reaches up to 70% by weight in high-grade deposits, which is why it has always been the preferred feedstock for iron production over alternatives like magnetite. The commercially assessed additive form of ferric oxide contains between 57% and 69% iron (Fe).

1.3 Manufacturing and Common Preparations

Three manufacturing routes are described for ferric oxide: mining, synthetic, and derusting. It contains between 57% and 66% (mining), 68% (synthetic), and 69% (derusting) iron (Fe) depending on the production method.

Synthetic pigment is made by heating iron sulfate with quicklime in a furnace. A second preparatory technique involves calcining iron sulfate in the presence of air at high temperatures. Natural iron oxides are mined either as the mineral hematite (Fe₂O₃) or as hematite in its hydrated form.

Ferric oxide is also synthesized in the laboratory through electrolysis of sodium bicarbonate solution, which acts as an inert electrolyte, and an iron anode.

In commercial and regulatory settings, ferric oxide appears in several principal forms:

• Pigment-grade powder — red iron oxide (Fe₂O₃) is an inorganic pigment of either natural or synthetic origin.
• Ochre — an earthy pigment containing ferric oxide, typically with clay, which varies in colour from dark red to brown to yellow.
• Nanoparticulate form — iron-oxide nanoparticles (IONPs) have garnered substantial attention in both research and technological domains due to their exceptional chemical and physical properties.
• Colloidal and surface-coated forms — used in biomedical research and diagnostic imaging agents.

---

2. Traditional and Historical Use

2.1 Prehistoric and Ancient Use of Ochre

164,000 years ago, people in what is now South Africa were grinding hematite to powder and using it for pigmentation, making it possibly the oldest documented human use of any mineral for a non-food purpose. Cave paintings dating back 40,000 years show hematite red ochre applied to rock walls. Hematite residues have been found in graves from 80,000 years ago.

Ancient cave paintings, such as those in Lascaux, France, prominently feature ochre. Indigenous Australians have used ochre for body painting and rock art for over 40,000 years.

The uses attributed to ochre in archaeological and ethnographic records extend well beyond decoration. A selection of documented and hypothesized ochre applications, modern and ancient, includes mosquito repellent, sunscreen, hide preservative, ingredient in composite tool hafting adhesives, red pottery slip, personal adornment/cosmetic/medicine, grave good, engraving substrate, and rock art pigment.

2.2 Ancient Egyptian and Greco-Roman Use

Red ochre was used in ancient Egypt for tomb painting and rituals. It was used for painting tombs in ancient Egypt and symbolized life and protection. In ancient Egypt, hematite was ground for cosmetics including lipstick and blush.

Naturally occurring color additives from vegetable and mineral sources were used to color foods, drugs, and cosmetics in ancient times. Paprika, turmeric, saffron, iron and lead oxides, and copper sulfate are some examples. Ochre's use in the Greco-Roman world is a documented area of scholarly inquiry.

2.3 Indigenous Australian Use

Traditionally, the Noongar people of southwestern Australia inhabited an environment where fresh water was a scarce resource during a large portion of the year, and in order to maintain bodily cleanliness they devised an effective substitute for water — a topical unguent known as wilgi made from a mixture of ochre (iron oxide) and animal fat. In Noongar culture, wilgi as a bodily emollient was used for many different purposes including as a skin protectant shielding the body from the adverse effects of the sun's ultraviolet rays.

2.4 Traditional Indian and Ayurvedic Use

In Ayurveda, and for hundreds of years in India, red ochre has been utilized in conventional remedies and cosmetics. It has been used as a cooling and healing medicinal paste and an herbal skin pigment. Note: these traditional claims have not been independently validated in controlled human studies.

2.5 Use as a Medicinal Colorant

Ochres have been widely employed for decorative and artistic purposes since the dawn of prehistory; ochres have also found medicinal applications. As pigments and excipients, iron oxides have long been incorporated into pharmaceutical coatings to color tablet dosage forms for visual identification and patient compliance, a practice that continues to the present.

---

3. Key Constituents and Chemical Composition

Ferric oxide as a pure substance is a single inorganic compound (Fe₂O₃) without secondary phytochemical constituents. The relevant compositional considerations are as follows:

• Iron content: The additive form of ferric oxide contains between 57% and 69% iron (Fe) depending on the manufacturing route.
• Crystalline polymorphs: The alpha polymorph (α-Fe₂O₃), corresponding to the mineral hematite, is the most thermodynamically stable form and the most prevalent in nature and industry. Red iron oxide Fe₂O₃ (CI 77491) is considered very stable, in contrast to black iron oxide Fe₃O₄ (CI 77499, stable) and yellow iron oxide FeOOH (CI 77492, unstable).
• Trace impurities: Depending on the manufacturing source, ferric oxide may contain nickel, chromium, and other trace metals. Due to nickel content, certain forms of ferric oxide should be regarded as a dermal and respiratory sensitiser, and inhalation of ferric oxide, along with contained chromium and nickel, poses a hazard.
• Ochre matrix: The primary ingredient of red earth pigments is octahedral iron oxide (haematite), in addition to varying amounts of quartz and clay minerals. Ochre is a clay colored by varying amounts of hematite, ranging from 20 to 70%.

---

4. Mechanisms of Action — Iron Biochemistry

4.1 The Iron Oxidation State Problem

Ferric oxide supplies iron exclusively in the Fe³⁺ (ferric) oxidation state. This has fundamental consequences for biological absorption. Iron is an essential element of various metabolic processes in humans, including DNA synthesis, electron transport, and oxygen transport. Unlike other minerals, iron levels in the human body are controlled only by absorption.

As most non-heme iron in the diet is in the ferric form, it first needs to be reduced to Fe²⁺ before it can be absorbed; this can be achieved by the actions of the membrane-bound ferric reductase duodenal cytochrome B (DCYTB or CYBRD1), which is expressed on the apical brush border membrane of intestinal epithelial cells. Ferrous iron is then transported across the apical membrane of enterocytes by the divalent metal transporter 1 (DMT1), an integral 12 transmembrane domain protein that has the ability to transport a number of divalent cations including Fe²⁺.

4.2 The Role of Duodenal Cytochrome b (Dcytb)

Dietary iron absorption is regulated by duodenal cytochrome b (Dcytb), an integral membrane protein that catalyzes reduction of non-heme Fe³⁺ by electron transfer from ascorbate across the membrane. This step is essential to enable iron uptake by the divalent metal transporter.

Since DMT-1 favors the absorption of divalent metal including Fe²⁺, the reduction of Fe³⁺ to Fe²⁺ by Dcytb in the duodenum is essential for effective intestinal iron absorption. Dcytb utilizes ascorbate in the cytoplasm as an electron donor to reduce apical Fe³⁺.

Hypoxia inducible factor (HIF) signaling was induced in the intestine following acute iron deficiency in the duodenum, resulting in activation of DcytB and DMT1 expression and an increase in iron uptake. DcytB and DMT1 were demonstrated as direct HIF-2α target genes. This regulatory relationship means that iron absorption efficiency is upregulated physiologically during iron deficiency.

4.3 Post-Absorption Iron Handling

Once iron is imported into enterocytes, it can be stored by binding to ferritin or exported into the circulation through the only iron exporter, ferroportin-1 (FPN1). Systemic iron levels are regulated by hepcidin, hypoxia, and inflammation.

In the human body, iron exists mainly in erythrocytes as the heme compound hemoglobin (approximately 2 g of iron in men and 1.5 g in women), to a lesser extent in storage compounds (ferritin and hemosiderin), and in muscle cells as myoglobin.

4.4 Why Ferric Oxide Has Poor Bioavailability as an Iron Source

Bioavailability of iron from ferric preparations is 3 to 4 times less than that of conventional ferrous sulfate preparations. This is due to the extremely poor solubility of ferric iron in alkaline media and the fact that ferric iron needs to be transformed into ferrous iron before being absorbed.

Trivalent iron in simple compounds like ferric ammonium citrate or in low- and high-molecular weight carbohydrate complexes of ferric hydroxide is so poorly available for intestinal iron absorption in man that it cannot be used for fast and reliable oral iron therapy with reasonably low doses as can easily be practiced with quick-release preparations of ferrous sulfate.

Ferric oxide, used as a coloring agent, is considered among the poorest of inorganic iron sources, although it is capable of impairing copper absorption. Ferric oxide should not be considered as an iron source capable of meeting the iron requirements of animals.

The absorption of commonly used ferrous iron salts from intestinal segments at neutral to slightly alkaline pH is low, mainly because soluble ferrous iron is easily oxidized to poorly soluble ferric iron, and because ferrous iron, but not ferric iron, is carried by the divalent metal transporter DMT-1.

4.5 Dietary Factors Modifying Ferric Iron Absorption

It is well known that dietary factors modify non-heme iron absorption. Ascorbic acid increases iron absorption, whilst phytate, calcium, and polyphenols decrease it. Additionally, the iron status of the organism plays an important role: high iron stores are related to low absorption rates, and vice versa.

Non-heme iron absorption is enhanced by co-ingestion of meat, fish, poultry, or dietary vitamin C, which reduces non-heme iron from its ferric (Fe³⁺) to ferrous (Fe²⁺) form, which is more readily absorbed. Absorption may be improved if treatment is taken with ascorbic acid or on an empty stomach to increase or maintain gastrointestinal acidity.

---

5. Scientific Evidence by Area of Use

5.1 As an Oral Iron Source / Nutritional Iron Supplement

Evidence strength: Weak to absent for ferric oxide specifically.

Ferric oxide is listed as a nutrient and dietary supplement that is a source of iron. However, the scientific and regulatory evidence strongly casts doubt on its value as a nutritional iron source.

As reviewed in a 2012 clinical overview published in The Scientific World Journal: In clinical practice, bivalent iron salts such as ferrous sulfate, ferrous gluconate, and ferrous fumarate are more widely used and are preferred over ferric iron preparations, as recommended by the WHO.

A comprehensive PubMed-indexed literature review (Palacios, 2012) found that ferrous sulfate (FS) preparations usually present good bioavailability (between 10 and 15%), while bioavailability of iron from ferric preparations is 3 to 4 times less than that of conventional FS. This is due to the extremely poor solubility of ferric iron in alkaline media and the fact that ferric iron needs to be transformed into ferrous iron before being absorbed.

A separate PubMed study examining bioavailability of trivalent iron across oral preparations concluded that humans absorb ferrous iron between 4 and 10 times (on average about 5 times) better than ferric iron across available results from critical whole-body retention measurements.

The EFSA FEEDAP Panel, in its 2016 scientific opinion specifically on ferric oxide as a feed additive, concluded that ferric oxide should not be considered as an iron source capable of meeting the iron requirements of animals. The EFSA FEEDAP Panel could not conclude on the safety of ferric oxide for the target animals owing to: (i) the application of ferric oxide red is for all animal species, (ii) lifetime administration to animals is not excluded, and (iii) a sufficient biological and toxicological database was not available.

Some 4 to 10% of dietary non-heme iron is usually absorbed, depending on the specific chemical forms, other dietary components such as vitamin C and amino acids, inhibitors such as phytic acid, and the body's stores of iron. Ferric oxide is considered to be at the lower extreme of this already modest range.

5.2 Ferric Iron Forms With Improved Bioavailability (Context: Comparative to Ferric Oxide)

While ferric oxide itself is a poor iron source, several other ferric-form supplements have been developed specifically to address the bioavailability challenge. These are distinct from ferric oxide but are relevant for understanding where ferric oxide sits on the spectrum:

• Ferric maltol: Ferric maltol is a newer oral iron replacement therapy designed to optimize iron absorption while reducing the gastrointestinal adverse events associated with unabsorbed free iron. It has been studied in clinical trials involving almost 750 adults and adolescents with iron-deficiency anemia associated with IBD, CKD, and other underlying conditions.
• Ferric polymaltose complex: In both experimental animals and human subjects, iron absorption over a wide dosage range was quantitatively equivalent from ferrous salts and a ferric polymaltose complex under basal conditions. This comparable bioavailability was maintained when demand was increased by iron depletion or erythroid stimulation. This common pattern for iron retention from both salt and complex supports the interchangeable use of these products in therapy of absolute iron deficiency.
• Iron oxide/hydroxide nanoparticles (charged shells): For nanoparticles with a negatively charged shell, iron uptake was about 40 times higher compared to those with neutral hydrophilic carbohydrate shell or ferric chloride, and in the same range as ferrous sulfate.

5.3 As a Colorant and Excipient in Pharmaceuticals and Cosmetics

Evidence strength: Well-established regulatory approval; no therapeutic claims.

As FDA-approved Pigment Brown 6 and Pigment Red 101, ferric oxide is approved for use in cosmetics. Beyond historical use, iron oxide pigments derived from hematite and synthetic iron oxides remain FDA-approved colorants in cosmetics today.

Ferric oxide is widely used as an excipient in oral pharmaceutical products to color tablet coatings. Naturally occurring color additives from vegetable and mineral sources have been used to color foods, drugs, and cosmetics in ancient times, including iron and lead oxides.

Iron oxide pigments, historically used in art and tattooing, remain widely applied today, particularly in the permanent makeup and medical dermopigmentation industries. The benefits of iron oxide pigments include their low price and excellent colour robustness toward sun exposure and other ambient conditions.

Although iron oxide pigments are generally not associated with immediate allergic reactions, adverse reactions can occur under specific conditions. A precautionary recommendation is to ensure adequate iron levels in iron-deficient patients prior to dermopigmentation, as transdermal absorption of iron from the tattoo site may occur.

5.4 Ferric Oxide Nanoparticles in Biomedical Applications (Investigational)

Evidence strength: Preliminary to moderate (mostly preclinical; some clinical translation for MRI contrast agents).

Superparamagnetic IONPs (SPIONPs) have been used for the diagnosis and treatment of cancer cells. IONPs have been widely reported for biomedical applications, such as contrast agents in magnetic resonance imaging (MRI), nanoplatforms for targeted drug delivery, cell labeling, and magnetic hyperthermia for the treatment of cancer cells.

Iron oxide nanoparticles in clinical trials have been approved by the FDA since 1996. Typical examples of coating agents include dextran/carboxydextran in Ferumoxtran, Ferumoxide, and Ferucarbotran; PEG in Feruglose; and aminosilane in Nanotherm™. Ferumoxytol is a polyglucose-sorbitol-carboxymethyl-ether-coated γ-Fe₂O₃ that was developed and approved in 2000 as an MRI contrast agent for many cancers.

Magnetic nanoparticles/iron oxide nanoparticles (magnetite Fe₃O₄ and maghemite γ-Fe₂O₃) have been under intensive investigation since they show great potential for biomedical applications, such as tumor imaging (MRI), radiolabelling and internal radiotherapy, hyperthermia, gene therapy, biomolecule separation, and drug delivery.

Several nanomedicines, which are combinations of organic compounds incorporated into IONPs, have already been approved by the USFDA and the European Medicine Agency (EMA) for preclinical and clinical trials. However, most of these drugs were rejected after preclinical trials due to issues of biocompatibility, agglomeration, and toxicity.

Targeted delivery systems based on surface modification of magnetic iron oxide nanoparticles exhibit significant potential as an advanced platform for early clinical diagnosis, real-time imaging, and precision adjuvant therapy, owing to their inherent MRI, biocatalytic activity (nanoenzymes), magnetic hyperthermia, and homologous targeted delivery of chemotherapeutic and gene therapy drugs. These applications remain largely in the investigational stage, with few having achieved broad clinical use.

---

6. Body Systems and Health Areas Associated with Ferric Oxide

6.1 Hematopoietic and Erythropoietic System

Iron deficiency is the most common cause of anemia globally and is frequently reported in patients with underlying inflammatory conditions, such as inflammatory bowel disease (IBD) and chronic kidney disease (CKD). Ferric oxide, as an iron-containing compound, is conceptually associated with the prevention and treatment of iron-deficiency anemia; however, its practical utility in this role is severely limited by its extremely poor bioavailability, as established by the comparative clinical literature.

In the human body, iron exists mainly in erythrocytes as the heme compound hemoglobin (approximately 2 g of iron in men and 1.5 g in women), to a lesser extent in storage compounds (ferritin and hemosiderin), and in muscle cells as myoglobin. Iron is an essential element of various metabolic processes in humans, including DNA synthesis, electron transport, and oxygen transport.

6.2 Gastrointestinal System

The low pH of gastric acid in the proximal duodenum allows the ferric reductase enzyme duodenal cytochrome B (Dcytb), on the brush border of the enterocytes, to convert insoluble ferric (Fe³⁺) to absorbable ferrous (Fe²⁺) ions. Gastric acid production plays a key role in plasma iron homeostasis.

Conditions like achlorhydria, atrophic gastritis, Helicobacter pylori infection, celiac disease, small bowel resection, and post-gastrectomy or vagotomy can impair iron absorption due to reduced gastric acidity. These conditions further reduce the already limited absorption of ferric oxide, since they impair the acid-dependent reduction of Fe³⁺ to Fe²⁺.

Unabsorbed iron can form reactive hydroxyl radicals in the gut, leading to mucosal irritation or damage. The resulting gastrointestinal adverse events, such as nausea, epigastric discomfort, and constipation, may reduce patients' willingness to continue treatment. Unabsorbed iron may also affect the gut microbiome and can trigger disease flares in patients with IBD.

6.3 Respiratory System (Occupational Context)

Long-term inhalation exposure to iron has resulted in mottling of the lungs, a condition referred to as siderosis. The OSHA-established permissible exposure limit for iron oxide fume is designed to protect workers from developing siderosis, a benign pneumoconiosis that occurs after many years of exposure to levels of iron oxide dust or fume in excess of 15 mg/m³, and accumulation of iron dust in the lungs associated with ferric oxide exposure.

The presence of iron oxide dust or fume in the lung causes a pigmentation (termed siderosis) that is responsible for the changes seen in exposed individuals' chest X-rays. Siderosis is believed not to progress to fibrosis, and 6 to 10 years of exposure to about 15 mg/m³ iron oxide dust is required before this condition develops.

6.4 Oncology and Imaging (Investigational)

Among the various nanomaterials under investigation, iron oxide nanoparticles have garnered significant interest due to their unique magnetic properties, biocompatibility, and tunable surface chemistry. These properties allow IONPs to serve as multifunctional agents in targeted drug delivery, magnetic resonance imaging (MRI), hyperthermia therapy, and biosensing applications — especially in cancer diagnostics and treatment.

6.5 Dermatology and Skin

Iron oxide has a documented topical use spanning tens of thousands of years. In Noongar culture, wilgi as a bodily emollient was used for many different purposes including as a skin protectant shielding the body from the adverse effects of the sun's ultraviolet rays. Modern cosmetic iron oxide pigments retain FDA approval for use in a variety of topical preparations including foundation, concealer, and other color cosmetics. There is limited controlled human research specifically on ferric oxide as a topical therapeutic agent, and no approved therapeutic skin claims exist.

---

7. Dosage Forms and Dosages Reported in Studies

Ferric oxide itself, in the bulk Fe₂O₃ form, does not have an established human therapeutic dose, because the scientific literature does not support its use as an effective oral iron supplement. The following dosage-related information reflects the contexts in which it has been studied or regulated:

• As a colorant/excipient in oral drug products and cosmetics: Ferric oxide is used in trace amounts as a coating colorant in tablets and as a pigment in cosmetics. No minimum or maximum therapeutic dose applies; quantities used are governed by good manufacturing practice and FDA/EMA color additive regulations. Synthetic iron oxide is approved for specific uses in animal food under 21 CFR 73.32 and related sections.
• As a feed additive (animal nutrition, EFSA assessment): Iron oxides black, red, and yellow are intended to be used as colorings to add and restore color to feedingstuffs at a recommended concentration between 500 and 1,200 mg/kg.
• As a research preparation (ferric iron-organic acid, human absorption study): Methyl-cellulose capsules containing single doses of ferric iron oxide–organic acid preparations (Fe-OAs) at 60 mg elemental iron equivalent were given to subjects to determine iron absorption and bioavailability. This was a small, first-in-human pilot study with limited generalizability.
• Ferric oxide nanoparticles (inhalation toxicology study in rats): Male rats were exposed nose-only to aerosols of γ-Fe₂O₃ nanoparticles at concentrations of 0.56, 1.63, and 4.92 mg/m³ for 6 hours/day, 5 days/week, over 28 days, followed by recovery periods of 7 and 28 days. This was a preclinical, non-human study.
• Occupational exposure limit (OSHA/NIOSH): OSHA has established a permissible exposure limit for iron oxide fume to protect workers from siderosis associated with exposure in excess of 15 mg/m³.

---

8. Safety Considerations and Interactions

8.1 Oral Ingestion

In the context of its conventional uses as a coloring agent and excipient, ferric oxide ingested in the quantities present in pharmaceutical coatings or cosmetically-grade preparations is generally considered safe by regulatory bodies. The extremely poor oral bioavailability of ferric oxide means that little iron from the compound reaches systemic circulation. Regarding the very low absorption of iron from the ferric oxide by target animals and the homoeostatic regulation of iron metabolism in animals, any influence of feeding the ferric oxide on the iron content of edible tissues and products is not expected. The use of ferric oxide in animal nutrition is unlikely to result in a direct exposure of the consumer to this oxide.

Extremely large oral dosages may produce gastrointestinal disturbances. For context on iron toxicity broadly: cellular toxicity occurs with the absorption of excessive quantities of ingested iron. Severe overdose causes impaired oxidative phosphorylation and mitochondrial dysfunction, which can result in acidosis and cellular death. The liver is one of the organs most affected by cellular iron toxicity, but other organs such as the heart, kidneys, lungs, and the hematologic systems may also be impaired. This risk is primarily associated with more bioavailable ferrous iron forms, not ferric oxide per se, given the latter's negligible absorption.

8.2 Inhalation Hazard

Ferric oxide is an irritant to skin and eyes by mechanical action. Owing to the nickel content in the additive, ferric oxide should be regarded as a dermal and respiratory sensitiser. Inhalation of ferric oxide, and the contained chromium and nickel, is a hazard; as exposure by inhalation is likely, handling ferric oxide would be a risk for the users.

Fine/micron-sized iron oxide particulates are incidentally released from a number of industrial processes, including iron ore mining, steel processing, welding, and pyrite production. Some research suggests that occupational exposure to these particulates is linked to an increased risk of adverse respiratory outcomes, whereas other studies suggest that iron oxide is biologically benign.

Relevant in vivo studies suggest that pulmonary exposure to IONPs may induce inflammation, pulmonary fibrosis, genotoxicity, and extra-pulmonary effects. However, a 28-day rat inhalation study at concentrations up to 4.92 mg/m³ showed no treatment-related effects, including clinical signs, body weight, hematology, serum biochemistry, or histopathology.

8.3 Genotoxicity Concern

As there is concern about the possible genotoxicity of ferric oxide, any route of exposure should be considered as hazardous in the context of the EFSA assessment of industrial-grade ferric oxide feed additives. This conclusion was specific to the bulk industrial material, which may contain trace heavy metals including chromium and nickel, and should not be conflated with the pharmaceutical-grade or cosmetic-grade ferric oxide used in controlled applications.

8.4 Interaction with Copper Absorption

Ferric oxide, even when used as a coloring agent, is capable of impairing copper absorption. This interaction is consistent with the general competition among divalent and trivalent metals for intestinal metal transporters. However, this has been noted in the context of animal nutrition research; its clinical significance in humans at the doses used in pharmaceutical coatings is not established in the available literature.

8.5 Interactions With Reducing Agents and Dietary Factors

Dietary factors modify non-heme iron absorption significantly. Ascorbic acid increases iron absorption, while phytate, calcium, and polyphenols decrease it. In theory, co-administration of ferric oxide with high-dose ascorbic acid could modestly increase conversion of Fe³⁺ to Fe²⁺ and thereby increase iron absorption, but no controlled clinical studies in humans have specifically examined this interaction for ferric oxide (Fe₂O₃) as distinct from other ferric iron compounds.

8.6 Dermopigmentation (Tattooing/Permanent Makeup)

Although iron oxide pigments are generally not associated with immediate allergic reactions, adverse reactions can occur under specific conditions. A precautionary recommendation is to ensure adequate iron levels in iron-deficient patients prior to dermopigmentation, as transdermal absorption of iron from the tattoo site may occur.

8.7 Regulatory Safety Status Summary

• FDA (cosmetics/drugs): Ferric oxide is FDA-approved as Pigment Brown 6 and Pigment Red 101 for use in cosmetics. It is also used as a colorant in oral pharmaceutical tablet coatings.
• EFSA (feed additives): The EFSA FEEDAP Panel could not conclude on the safety of ferric oxide for use as a nutritional feed additive for all animal species, owing to gaps in the biological and toxicological database.
• Occupational exposure (NIOSH/OSHA): An occupational exposure limit has been established to protect workers from siderosis associated with iron oxide dust or fume exposures in excess of 15 mg/m³.

---

9. Summary of Evidence Strength

Ferric oxide occupies a complex position in the landscape of dietary supplements and nutritional ingredients. It is listed as a nutrient and dietary supplement that is a source of iron, but the totality of the scientific evidence — including comparative bioavailability studies, systematic reviews, and regulatory agency assessments — indicates that it is one of the least bioavailable forms of supplemental iron available. Its primary validated uses are as an approved colorant in cosmetic, food, and pharmaceutical applications, and — in nanoparticulate form — as an investigational platform for MRI contrast imaging and targeted drug delivery. Its traditional use spans more than 100,000 years as a pigment and topical preparation, with limited but documented use as a medicinal agent in various ancient cultures. Clinical therapeutic evidence for ferric oxide (in bulk Fe₂O₃ form) as an oral iron supplement is essentially absent, and both EFSA and the comparative iron bioavailability literature strongly advise against its use as an iron source.

References

• Palacios S. Ferrous versus Ferric Oral Iron Formulations for the Treatment of Iron Deficiency: A Clinical Overview. Scientific World Journal. 2012. PMC3354642.
• Bioavailability of iron from ferrous salts and ferric polymaltose complex. PubMed PMID 3566865.
• Bioavailability of trivalent iron in oral iron preparations. PubMed PMID 1174047.
• Iron Replacement Therapy with Oral Ferric Maltol: Review of the Evidence and Expert Opinion. PMC8509126.
• Iron oxide/hydroxide nanoparticles and Caco-2 iron uptake. PubMed PMID 22587679.
• EFSA FEEDAP Panel. Safety and efficacy of iron compounds (E1) as feed additives for all species: ferric oxide. EFSA Journal 2016;14(6):4508. PMC11847998.
• EFSA FEEDAP Panel. Safety and efficacy of ferric oxide as feed additive. EFSA Journal. 2016.
• EFSA. Safety and efficacy of iron oxide black, red and yellow for all animal species. EFSA Journal. 2016.
• Ganasen M et al. Structural basis for promotion of duodenal iron absorption by enteric ferric reductase with ascorbate. Communications Biology. 2018. PMC6123691.
• Srole DN, Chang MJ. Ironing out mechanisms of iron homeostasis and disorders of iron deficiency. Journal of Clinical Investigation. 2021.
• Molecular mechanisms involved in intestinal iron absorption. PMC4611193.
• The Regulation of Iron Absorption and Homeostasis. PMC5198508.
• Intestinal Hypoxia Inducible Transcription Factors are Essential for Iron Absorption Following Iron Deficiency. PMC2659630.
• Biochemistry, Iron Absorption. StatPearls. NCBI Bookshelf NBK448204.
• McKie AT et al. An iron-regulated ferric reductase associated with the absorption of dietary iron. PubMed PMID 11230685.
• Advances in the Synthesis and Application of Magnetic Ferrite Nanoparticles for Cancer Therapy. PMC9145864.
• Iron oxide based magnetic nanoparticles for hyperthermia, MRI and drug delivery applications: a review. PMC11995399.
• Potential Toxicity and Underlying Mechanisms Associated with Pulmonary Exposure to Iron Oxide Nanoparticles. PMC5666472.
• Inhalation toxicity, pulmonary clearance, and biotransformation of ferric oxide nanoparticles in rats. PMC12829270.
• NIOSH/CDC. 1988 OSHA PEL Project — Iron Oxide Fume (1309-37-1).
• FDA. Color Additives History.
• FDA. Regulatory Status of Color Additives.
• ClinicalTrials.gov NCT01991600. A Pilot Study to Assess the Influence of Dietary Organic Acids on Iron Absorption.
• Iron from nanostructured ferric phosphate: absorption and biodistribution in mice and bioavailability in iron deficient anemic women. PMC8857185.
• Glycoprotein Matrix-Bound Iron Improves Absorption Compared to Ferrous Bisglycinate Chelate and Ferrous Fumarate: A Randomized Crossover Trial. PMC11972659.
• First evidence of Pleistocene ochre production from bacteriogenic iron oxides. ScienceDirect. 2020.
• Iron Oxide-Based Pigments and Their Use in History. ResearchGate.
• What Hematite Is Used For: From Iron Ore to Everyday Applications. Elchemy. 2026.
• Ochre: an ancient health-giving cosmetic. Anthropology from the Shed. 2023.
• Council for Responsible Nutrition (CRN). Vitamin and Mineral Safety, 3rd Edition (2013): Iron.
• Beyond the ink: cellular and molecular effects of iron-based pigments on macrophages. bioRxiv. 2025.